| Effectiveness of the BNT162b2 Covid-19 Vaccine against the B. 1.1. 7 and B. 1.351 Variants LJ Abu-Raddad, H Chemaitelly, AA Butt New England Journal of Medicine 385 (2), 187-189, 2021 | 1098 | 2021 |
| Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar H Chemaitelly, P Tang, MR Hasan, S AlMukdad, HM Yassine, ... New England Journal of Medicine 385 (24), e83, 2021 | 874 | 2021 |
| Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies M Kanekiyo, CJ Wei, HM Yassine, PM McTamney, JC Boyington, ... Nature 499 (7456), 102-106, 2013 | 844 | 2013 |
| Pre-fusion structure of a human coronavirus spike protein RN Kirchdoerfer, CA Cottrell, N Wang, J Pallesen, HM Yassine, HL Turner, ... Nature 531 (7592), 118-121, 2016 | 825 | 2016 |
| Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection HM Yassine, JC Boyington, PM McTamney, CJ Wei, M Kanekiyo, ... Nature medicine 21 (9), 1065-1070, 2015 | 659 | 2015 |
| Effects of previous infection and vaccination on symptomatic omicron infections HN Altarawneh, H Chemaitelly, HH Ayoub, P Tang, MR Hasan, ... New England Journal of Medicine 387 (1), 21-34, 2022 | 470 | 2022 |
| BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar P Tang, MR Hasan, H Chemaitelly, HM Yassine, FM Benslimane, ... Nature medicine 27 (12), 2136-2143, 2021 | 457 | 2021 |
| Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms MK Smatti, FS Cyprian, GK Nasrallah, AA Al Thani, RO Almishal, ... Viruses 11 (8), 762, 2019 | 447 | 2019 |
| Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2 N Younes, DW Al-Sadeq, H Al-Jighefee, S Younes, O Al-Jamal, HI Daas, ... Viruses 12 (6), 582, 2020 | 428 | 2020 |
| Protection against the Omicron variant from previous SARS-CoV-2 infection HN Altarawneh, H Chemaitelly, MR Hasan, HH Ayoub, S Qassim, ... New England Journal of Medicine 386 (13), 1288-1290, 2022 | 417 | 2022 |
| mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar H Chemaitelly, HM Yassine, FM Benslimane, HA Al Khatib, P Tang, ... Nature medicine 27 (9), 1614-1621, 2021 | 404 | 2021 |
| Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera JO Ngwuta, M Chen, K Modjarrad, MG Joyce, M Kanekiyo, A Kumar, ... Science translational medicine 7 (309), 309ra162-309ra162, 2015 | 375 | 2015 |
| Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar LJ Abu-Raddad, H Chemaitelly, HH Ayoub, S AlMukdad, HM Yassine, ... New England Journal of Medicine 386 (19), 1804-1816, 2022 | 371 | 2022 |
| Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines Q Fernandes, VP Inchakalody, M Merhi, S Mestiri, N Taib, ... Annals of medicine 54 (1), 524-540, 2022 | 366 | 2022 |
| Evaluation of candidate vaccine approaches for MERS-CoV L Wang, W Shi, MG Joyce, K Modjarrad, Y Zhang, K Leung, CR Lees, ... Nature communications 6 (1), 7712, 2015 | 319 | 2015 |
| Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses MG Joyce, AK Wheatley, PV Thomas, GY Chuang, C Soto, RT Bailer, ... Cell 166 (3), 609-623, 2016 | 306 | 2016 |
| Structural and genetic basis for development of broadly neutralizing influenza antibodies D Lingwood, PM McTamney, HM Yassine, JRR Whittle, X Guo, ... Nature 489 (7417), 566-570, 2012 | 289 | 2012 |
| Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses M Kanekiyo, MG Joyce, RA Gillespie, JR Gallagher, SF Andrews, ... Nature immunology 20 (3), 362-372, 2019 | 244 | 2019 |
| Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting Clinical Infectious Diseases, 2020 | 243* | 2020 |
| Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar H Chemaitelly, HH Ayoub, S AlMukdad, P Coyle, P Tang, HM Yassine, ... Nature communications 13 (1), 3082, 2022 | 224 | 2022 |
Gheyath K. NasrallahAssociate Professor of Biomedical Science, College of Health Sciences, QU health, Qatar University在 qu.edu.qa 的电子邮件经过验证
